MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2023-24)
- Udyam number
- UDYAM-HP-10-0000217
Nanz Med Science Pharma Private Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹258.64 Cr
▲ 10% YoY
Net profit · FY 2025
₹12.45 Cr
Net margin 4.8%
EBITDA · FY 2025
₹25.6 Cr
EBITDA margin 9.9%
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹12.11 Cr
Issued & subscribed
Open charges
₹105.15 Cr
Satisfied ₹46.5 Cr
Company age
20 yrs
Est. 2006
Employees · EPFO
393
Provident fund records
About Nanz Med Science Pharma Private Limited
Data last updated:
Nanz Med Science Pharma Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 December 2006 and has been in existence for over 20 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24100DL2006PTC156756. Its GSTIN is 07AACCN5552B1ZS (Delhi). The company holds 9 GST registrations, of which 5 are active.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.11 Cr. It is led by directors including Manmit Singh Malhotra (Managing Director) and Lakhvinder Pal Singh.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at C – 168 Ground Floor, Naraina Industrial Area Phase I, New Delhi, Delhi, India – 110028.
As per the financials filed for FY 2025, the company reported a revenue of ₹258.64 Cr, a growth of 10% compared to the previous year. For the same year it recorded a net profit of ₹12.45 Cr (net margin 4.8%) and EBITDA of ₹25.6 Cr (EBITDA margin 9.9%). Revenue has grown at a compounded annual rate (CAGR) of 17% over three years and 10% over five years.
The company has about 393 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Nanz MedScience Pharma. As per MCA filings, the company has open charges of ₹105.15 Cr and satisfied charges of ₹46.5 Cr on record. Court records list 40 cases involving the company, including 24 filed by the company and 16 filed against it; 7 cases are pending. The company has 8 deals on record (3 funding rounds, 3 secondary share transfers, 2 rights issues), with disclosed funding of ₹14.49 Cr; the latest was in March 2024. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 2 smaller; the largest is Panacea Biotec Pharma Limited with revenue of ₹265.23 Cr.
Nanz Med Science Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-HP-10-0000217). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nanzpharma.com.
Company details
CIN U24100DL2006PTC156756
Registration Number 156756
Incorporation Date 19 December 2006
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-HP-10-0000217
CIN history
Nanz Med Science Pharma has one previous CIN (Corporate Identification Number): U01403DL2006PTC156756. The current CIN is U24100DL2006PTC156756, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100DL2006PTC156756 | Current |
| U01403DL2006PTC156756 | Previous |
Key People
Manmit Singh Malhotra Managing Director Harpreet Singh Puri Additional Director Sunpreet Kaur Puri Additional Director Recognitions & Rankings of Nanz Med Science Pharma
Contact details
Nanz Med Science Pharma Private Limited's registered office is in New Delhi, Delhi. Its website is nanzpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressC – 168 Ground Floor, Naraina Industrial Area Phase I, New Delhi, Delhi, India – 110028
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Nanz Med Science Pharma Private Limited, buy the company report.
Comprehensive company report
Nanz Med Science Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Nanz Med Science Pharma operates one associated brand: Nanz MedScience Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provides contract-based pharmaceutical formulation research, manufacturing, and marketing services. | nanzpharma.com |
Business activity
The main business activity of Nanz Med Science Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Nanz Med Science Pharma Private Limited, buy the company report.
Financials of Nanz Med Science Pharma Private Limited
FY 2024 filings availableNanz Med Science Pharma Private Limited reported revenue of ₹258.64 Cr (up 10% YoY) for FY 2025.
Revenue · FY 2025
₹258.64 Cr ▲ 10%
Net profit · FY 2025
₹12.45 Cr margin 4.8%
EBITDA · FY 2025
₹25.6 Cr margin 9.9%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 10%
3 years · compounded
▲ 17%
5 years · compounded
▲ 10%
EBITDA CAGR growth
1 year
▲ 30%
3 years · compounded
▲ 33%
5 years · compounded
▲ 13%
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 10% growth in the latest year. EBITDA rose 30% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹25.6 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹12.45 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9.9% | ||||
| Net Profit Margin | 4.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Nanz Med Science Pharma Private Limited, buy the company report.
Board of directors of Nanz Med Science Pharma Private Limited
Nanz Med Science Pharma has 4 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manmit Singh Malhotra | Managing Director | 01 Apr 2009 | 17 Years 7 Months | Current |
| Harpreet Singh Puri | Additional Director | 15 Nov 2024 | 1 Years 11 Months | Current |
| Sunpreet Kaur Puri | Additional Director | 15 Nov 2024 | 1 Years 11 Months | Current |
| Lakhvinder Pal Singh | Director | 01 Oct 2007 | 19 Years 1 Months | Current |
Peer comparison
Nanz Med Science Pharma Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Panacea Biotec Pharma Limited | ₹265.23 Cr (FY 2025) | 26.0% | New Delhi, Delhi, India | |||
| Psychotropics India Limited | ₹261.89 Cr (FY 2025) | -8.0% | Faridabad, Haryana, India | |||
| Nanz Med Science Pharma Private Limitedthis company | ₹258.64 Cr (FY 2025) | ₹12.45 Cr | 4.8% | 10.0% | 393 | New Delhi, Delhi, India |
| Pretty Petals Private Limited | ₹251.52 Cr (FY 2025) | 21.0% | New Delhi, Delhi, India | |||
| East India Pharmaceutical Works Limited | ₹249.94 Cr (FY 2024) | Kolkata, West Bengal, India |
To see the full peer comparison of Nanz Med Science Pharma Private Limited, buy the company report.
Auditor
Nanz Med Science Pharma Private Limited is audited by DEEPAK GULATI AND ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DEEPAK GULATI AND ASSOCIATES | FY 2024 | 007545N |
Shareholding
The shareholding of Nanz Med Science Pharma Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Nanz Med Science Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹105.15 Cr
Satisfied charges
₹46.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Nov 2025 | 101184304 | Hdfc Bank Limited | ₹8.5 Lakh | Open | |
| 23 Dec 2024 | 101041345 | Others | ₹6 Cr | Open | |
| 15 Jan 2024 | 100852431 | Hdfc Bank Limited | ₹28.08 Lakh | Open | |
| 18 Dec 2023 | 100831940 | Tata Capital Financial Services Limited | ₹3 Cr | Open | |
| 15 Nov 2023 | 100858359 | Hdfc Bank Limited | ₹44 Lakh | Open |
To see the full charge records of Nanz Med Science Pharma Private Limited, buy the company report.
Total charge records: 16 View all charges
Deals & funding
Nanz Med Science Pharma Private Limited has 8 deals on record (3 funding rounds, 3 secondary share transfers, 2 rights issues), with disclosed funding of ₹14.49 Cr; the latest was in March 2024.
Total deals
8
Funding rounds
3
Secondary share transfers
3
Rights issues
2
Disclosed funding
₹14.49 Cr
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2024 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jan 2018 | Rights issue | ₹1.93 Cr | Investors: 4 individuals |
| Mar 2016 | Rights issue | ₹1.14 Cr | Investors: 2 individuals |
| Sep 2013 | Funding round | ₹87.1 Lakh | Investors: an individual |
| Feb 2012 | Funding round | ₹6.97 Cr | Investors: 2 individuals |
To see the full deal history of Nanz Med Science Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Nanz Med Science Pharma Private Limited has 40 court cases on record: 24 filed by Nanz Med Science Pharma, 16 filed against it. 7 cases are pending and 33 are disposed.
Total cases
40
Filed by the company
24
Filed against the company
16
Pending
7
Disposed
33
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 21 | 6 | 5 |
| District courts | 16 | 10 | 2 |
| Supreme Court | 2 | 0 | 0 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 40)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Sirmaur, Himachal Pradesh | Court case (Suit for Recovery) | Filed by the company against Goa Antibiotics and Pharmaceuticals Ltd | Pending |
| High Court | Court case (COMIP) | Filed against the company by Sun Pharmaceutical Industries Limited | Pending |
| High Court, MAHARASHTRA | Court case (CRR) | Filed against the company by Sun Pharmaceutical Industries Limited | Pending |
| District court, Bhopal, Madhya Pradesh | Court case (MJC AV) | Filed by the company against Managing Director MP Public Health Service Corporation Ltd and 2 others | Disposed |
| NCLT, Mumbai | Insolvency matter | Filed by the company against Elder Projects Limited | Disposed |
To see the full case history of Nanz Med Science Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Nanz Med Science Pharma Private Limited was last rated by Crisil on 15 Sep 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 15 Sep 2020 |
To see the full credit ratings and regulatory alerts of Nanz Med Science Pharma Private Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Nanz Med Science Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Nanz Med Science Pharma Private Limited has a workforce of 393 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Employee count
393
Active EPFO establishments
1
Employee growth
-16.7%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 393 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Nanz Med Science Pharma Private Limited, buy the company report.
GST
Nanz Med Science Pharma has 9 GST registrations: 5 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
9
Active
5
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AACCN5552B1ZS | Delhi | Active | 01 Jul 2017 |
| 02AACCN5552B1Z2 | Himachal Pradesh | Active | 01 Jul 2017 |
| 27AACCN5552B1ZQ | Maharashtra | Active | 04 Jul 2019 |
| 36AACCN5552B1ZR | Telangana | Active | 14 Oct 2024 |
To see the full GST registrations and return filing status of Nanz Med Science Pharma Private Limited, buy the company report.
Recent activity
Nanz Med Science Pharma Private Limited has 10 board changes on record since 2007: 4 appointments and 6 cessations. The latest: Harpreet Singh Puri was appointed as Additional Director on 15 Nov 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.09 Cr with Charge ID 101184304 was registered on 10 Nov 2025.
Charges
A charge with Hdfc Bank Limited of Rs. 90.05 Cr registered on 04 Feb 2016 with Charge ID 10620352 was modified on 31 Jul 2025.
Charges
A charge with Others amounted to Rs. 6.00 Cr with Charge ID 101041345 was registered on 23 Dec 2024.
Appointed
Harpreet Singh Puri was appointed as Additional Director.
Appointed
Sunpreet Kaur Puri was appointed as Additional Director.
AGM
Nanz Med Science Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Ceased
Lakhvinder Pal Singh ceased to be Director.
Ceased
Manmit Singh Malhotra ceased to be Director.
Charges
A charge registered on 20 Apr 2018 via Charge ID 100176513 with Others was fully satisfied on 20 Apr 2024.
Filing
Nanz Med Science Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.28 Cr with Charge ID 100852431 was registered on 15 Jan 2024.
Charges
A charge with Tata Capital Financial Services Limited amounted to Rs. 3.00 Cr with Charge ID 100831940 was registered on 18 Dec 2023.
26 earlier events are in the company report.
Frequently asked questions
Nanz Med Science Pharma is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 December 2006 (20+ years old) and is registered under CIN U24100DL2006PTC156756.
Nanz Med Science Pharma has 4 current directors:
- Manmit Singh Malhotra - Managing Director
- Harpreet Singh Puri - Additional Director
- Sunpreet Kaur Puri - Additional Director
- Lakhvinder Pal Singh - Director
The latest financial statements of Nanz Med Science Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Nanz Med Science Pharma is 07AACCN5552B1ZS, registered in Delhi. The company has 9 GST registrations in all, of which 5 are active and 4 are cancelled or inactive. Other active GSTINs include 02AACCN5552B1Z2 (Himachal Pradesh), 27AACCN5552B1ZQ (Maharashtra), 36AACCN5552B1ZR (Telangana).
The CIN (Corporate Identification Number) of Nanz Med Science Pharma is U24100DL2006PTC156756. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nanz Med Science Pharma has 40 court cases on record: 24 filed by the company and 16 filed against it. 7 are pending. Most are in the high courts.
Nanz Med Science Pharma was incorporated on 19 December 2006, making it 20+ years old. It is registered with the Registrar of Companies, Delhi.
Nanz Med Science Pharma has 8 deals on record (3 funding rounds, 3 secondary share transfers, 2 rights issues), with disclosed funding of ₹14.49 Cr; the latest was in March 2024.
The peers of Nanz Med Science Pharma by revenue are Panacea Biotec Pharma Limited, Psychotropics India Limited, Pretty Petals Private Limited, East India Pharmaceutical Works Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Harpreet Singh Puri was appointed as Additional Director on 15 Nov 2024. Sunpreet Kaur Puri was appointed as Additional Director on 15 Nov 2024. Lakhvinder Pal Singh ceased to be Director on 16 Aug 2024. Nanz Med Science Pharma has 10 board changes on record in total.
Yes, Nanz Med Science Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-HP-10-0000217).
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages